Vaxart Q2 revenue falls on lower government contract income

Vaxart

06/08/2026 21:19

Overview
US oral vaccine developer's Q2 revenue fell yr/yr, mainly on lower government contract revenue
Net loss for Q2 narrowed from prior year, reflecting lower R&D expenses
Company reported topline safety data from 400-person Phase 2b COVID-19 vaccine trial cohort

Outlook
Vaxart expects topline efficacy and safety data from its Phase 2b COVID-19 trial in H1 2027
Company anticipates cash runway into the second quarter of 2027
Vaxart is exploring business development partnerships and non-dilutive funding to extend cash runway

Result Drivers
TRIAL PROGRESS - Co reported topline safety data from 400-person Phase 2b COVID-19 vaccine trial cohort, with no vaccine-related serious adverse events
LOWER R&D SPENDING - Research and development expenses fell due to decreased clinical trial, personnel, facilities, and manufacturing costs
BARDA FUNDING - Additional BARDA contract funding supported continuation of Phase 2b COVID-19 study and next phase of data analysis

Company press release: ID:nGNXbYz5XP

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$27.19 mln
 
Q2 Net Loss
 
$13.49 mln
$29.78 mln (2 Analysts)
Q2 Operating Income
 
-$13.17 mln
-$29.95 mln (2 Analysts)
Q2 Pretax Loss
 
$13.47 mln
$29.78 mln (2 Analysts)
Q2 Loss Per Basic Share
 
$0.06
 
Q2 Operating Expenses
 
$40.36 mln
 

Reuters Recommended Reads
Aug 4 - BioNTech lowers 2026 sales outlook as COVID vaccine demand softens
Aug 6 - Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand
Aug 5 - Biomea Fusion Q2 loss narrows, cash runway into Q2 2027

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)